Clinical trial

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

NCT01937299

Study summary

ClinicalTrials.gov

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Vehicle Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Travoprost 0.004% ophthalmic solution Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-10-01

PhasePHASE4

Conditions

Ocular Hypertensionverified · MONDO: ocular hypertension

Open Angle Glaucomaverified · MONDO: open-angle glaucoma

Interventions

Brinzolamide 1%/brimonidine 0.2% ophthalmic suspensionDRUG

VehicleDRUG

Travoprost 0.004% ophthalmic solutionDRUG

Sponsors & collaborators

Alcon Researchlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01937299 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.